Skip to Main Content

Ketamine for severe adolescent depression: intermediate-term safety and efficacy

Conditions

Children's Health | Mental Health & Behavioral Research

Phase II-III

What is the purpose of this trial?

The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.

  • Trial with
    Klingenstein Third Generation Child and Adolescent Depression Fellowship
  • Start Date
    07/16/2019
  • End Date
    08/30/2023
Trial Image

For more information about this study, contact:

David Zakur

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/02/2019
  • Study HIC
    #2000023857